Fig. 3From: Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian studyProportion of patients under UST treatment with clinical response at week 8, biological response/remission up to week 16 and steroid-free remission at the end of follow-up. NRI nonresponder imputation, UST ustekinumabBack to article page